Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q2
$3.69M Sell
50,853
-274
-0.5% -$18.4K 0.06% 139
2017
Q1
$3.33M Sell
51,127
-28,015
-35% -$1.76M 0.06% 155
2016
Q4
$4.96M Sell
79,142
-7,100
-8% -$433K 0.1% 118
2016
Q3
$5.44M Buy
86,242
+10,122
+13% +$655K 0.1% 117
2016
Q2
$4.71M Sell
76,120
-545,118
-88% -$33.2M 0.09% 119
2016
Q1
$35.5M Buy
621,238
+1,289
+0.2% +$71.8K 0.71% 54
2015
Q4
$36.7M Buy
619,949
+853
+0.1% +$49.1K 0.71% 50
2015
Q3
$33.7M Sell
619,096
-262,307
-30% -$17.1M 0.68% 49
2015
Q2
$59.2M Buy
881,403
+3,998
+0.5% +$261K 1.06% 37
2015
Q1
$51.4M Sell
877,405
-338,828
-28% -$20.5M 0.93% 38
2014
Q4
$79.6M Buy
1,216,233
+107,520
+10% +$6.78M 1.48% 16
2014
Q3
$64M Buy
1,108,713
+1,055,835
+1,997% +$58.6M 1.21% 26
2014
Q2
$2.98M Buy
52,878
+10,654
+25% +$559K 0.05% 173
2014
Q1
$2.17M Buy
42,224
+20,808
+97% +$1.05M 0.04% 198
2013
Q4
$1.13M Buy
21,416
+140
+0.7% +$6.88K 0.02% 243
2013
Q3
$952K Sell
21,276
-2,088
-9% -$92.6K 0.02% 255
2013
Q2
$966K Buy
+23,364
New +$1.02M 0.02% 223

Other funds holding ABBV

Geneva Advisors's ABBV Position: Q2 2017 in Review

Geneva Advisors reduced its AbbVie (ABBV) stake by 0.54% in Q2 2017, selling an estimated $18.4K and leaving 50,853 shares worth $3.69M. The position accounts for 0.06% of the portfolio, ranked #139.

Geneva Advisors first reported a position in ABBV in Q2 2013 and has held it in 17 quarters since. The position peaked at $79.6M in Q4 2014. 1,763 funds tracked by Wall St. Rank hold ABBV as of Q2 2017.

  • Geneva Advisors held 50,853 shares of AbbVie worth $3.69M as of Q2 2017.
  • Geneva Advisors sold 274 AbbVie shares in Q2 2017, an estimated $18.4K.
  • AbbVie made up 0.06% of Geneva Advisors's portfolio in Q2 2017, its #139 holding.
  • Geneva Advisors first reported a position in AbbVie in Q2 2013 and has held it in 17 quarters since.
  • Geneva Advisors's AbbVie position peaked at $79.6M in Q4 2014.
  • 1,763 funds tracked by Wall St. Rank held AbbVie as of Q2 2017.

Based on Geneva Advisors's 13F filing for Q2 2017, filed 7 Aug 2017.